Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 5 |
List of Tables | 5 | 1 |
List of Figures | 6 | 1 |
Introduction | 7 | 1 |
Global Markets Direct Report Coverage | 7 | 1 |
Low Back Pain Overview | 8 | 1 |
Therapeutics Development | 9 | 1 |
Pipeline Products for Low Back Pain Overview | 9 | 1 |
Low Back Pain Therapeutics under Development by Companies | 10 | 2 |
Low Back Pain Pipeline Products Glance | 12 | 3 |
Late Stage Products | 12 | 1 |
Clinical Stage Products | 13 | 1 |
Early Stage Products | 14 | 1 |
Low Back Pain Products under Development by Companies | 15 | 1 |
Low Back Pain Companies Involved in Therapeutics Development | 16 | 20 |
Adynxx, Inc. | 16 | 1 |
Aestus Therapeutics, Inc. | 17 | 1 |
Array BioPharma Inc. | 18 | 1 |
Axsome Therapeutics Inc | 19 | 1 |
Boehringer Ingelheim GmbH | 20 | 1 |
Egalet Corporation | 21 | 1 |
Frontier Biotechnologies Co., Ltd | 22 | 1 |
Gador S.A. | 23 | 1 |
Grunenthal GmbH | 24 | 1 |
Hisamitsu Pharmaceutical Co., Inc. | 25 | 1 |
Immune Pharmaceuticals Inc. | 26 | 1 |
KPI Therapeutics, Inc. | 27 | 1 |
MD Biosciences GmbH | 28 | 1 |
Mesoblast Limited | 29 | 1 |
Nektar Therapeutics | 30 | 1 |
Orion Oyj | 31 | 1 |
Pacira Pharmaceuticals, Inc. | 32 | 1 |
Pfizer Inc. | 33 | 1 |
Stayble Therapeutics AB | 34 | 1 |
Sun Pharma Advanced Research Company Ltd. | 35 | 1 |
Low Back Pain Therapeutics Assessment | 36 | 10 |
Assessment by Monotherapy Products | 36 | 1 |
Assessment by Combination Products | 37 | 1 |
Assessment by Target | 38 | 2 |
Assessment by Mechanism of Action | 40 | 2 |
Assessment by Route of Administration | 42 | 2 |
Assessment by Molecule Type | 44 | 2 |
Drug Profiles | 46 | 34 |
(loxoprofen + methocarbamol) Drug Profile | 46 | 1 |
AB-001 Drug Profile | 47 | 1 |
ARRY-954 Drug Profile | 48 | 1 |
ATX-09002 Drug Profile | 49 | 1 |
AYX-2 Drug Profile | 50 | 1 |
bupivacaine Drug Profile | 51 | 2 |
cebranopadol Drug Profile | 53 | 3 |
dexmedetomidine hydrochloride Drug Profile | 56 | 2 |
Drug for Chronic Low Back Pain Drug Profile | 58 | 1 |
HP-3150 Drug Profile | 59 | 1 |
IG-8801 Drug Profile | 60 | 1 |
lidocaine hydrochloride Drug Profile | 61 | 2 |
MD-22 Drug Profile | 63 | 1 |
MPC-06ID Drug Profile | 64 | 3 |
NKTR-181 Drug Profile | 67 | 3 |
oxycodone hydrochloride ER Drug Profile | 70 | 2 |
SPARC-1401 Drug Profile | 72 | 1 |
tanezumab Drug Profile | 73 | 3 |
U-2902 Drug Profile | 76 | 2 |
zoledronic acid Drug Profile | 78 | 2 |
Low Back Pain Dormant Projects | 80 | 2 |
Low Back Pain Discontinued Products | 82 | 1 |
Low Back Pain Product Development Milestones | 83 | 4 |
Featured News &Press Releases | 83 | 1 |
Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science | 83 | 1 |
Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain | 84 | 1 |
Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms | 84 | 1 |
Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain | 85 | 2 |
Appendix | 87 | 2 |
Methodology | 87 | 1 |
Coverage | 87 | 1 |
Secondary Research | 87 | 1 |
Primary Research | 87 | 1 |
Expert Panel Validation | 87 | 1 |
Contact Us | 87 | 1 |
Disclaimer | 88 | 1 |